Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Beta-blockers for hypertension.

Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH.

Cochrane Database Syst Rev. 2017 Jan 20;1:CD002003. doi: 10.1002/14651858.CD002003.pub5. Review.

2.

Chronic β1-adrenoceptor blockade impairs ischaemic tolerance and preconditioning in murine myocardium.

See Hoe LE, Schilling JM, Busija AR, Haushalter KJ, Ozberk V, Keshwani MM, Roth DM, Toit ED, Headrick JP, Patel HH, Peart JN.

Eur J Pharmacol. 2016 Oct 15;789:1-7. doi: 10.1016/j.ejphar.2016.06.054. Epub 2016 Jun 30.

3.

High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy.

Everett BM, Zeller T, Glynn RJ, Ridker PM, Blankenberg S.

Circulation. 2015 May 26;131(21):1851-60. doi: 10.1161/CIRCULATIONAHA.114.014522. Epub 2015 Mar 30.

4.

Hypertension management: an update.

Nguyen Q, Dominguez J, Nguyen L, Gullapalli N.

Am Health Drug Benefits. 2010 Jan;3(1):47-56.

5.

Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease.

Tomiyama H, Yamashina A.

Int J Hypertens. 2014;2014:919256. doi: 10.1155/2014/919256. Epub 2014 Jan 30. Review.

6.

Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.

Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL.

BMJ. 2013 Oct 24;347:f6008. doi: 10.1136/bmj.f6008. Review.

7.

Prevalence and risk factors for resistant hypertension among hypertensive patients from a developing country.

Kumara WA, Perera T, Dissanayake M, Ranasinghe P, Constantine GR.

BMC Res Notes. 2013 Sep 21;6:373. doi: 10.1186/1756-0500-6-373.

9.

Comparative effectiveness of 2 β-blockers in hypertensive patients.

Parker ED, Margolis KL, Trower NK, Magid DJ, Tavel HM, Shetterly SM, Ho PM, Swain BE, O'Connor PJ.

Arch Intern Med. 2012 Oct 8;172(18):1406-12.

10.

Use of carvedilol in hypertension: an update.

Leonetti G, Egan CG.

Vasc Health Risk Manag. 2012;8:307-22. doi: 10.2147/VHRM.S31578. Epub 2012 May 18. Review.

11.

Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis.

Fretheim A, Odgaard-Jensen J, Brørs O, Madsen S, Njølstad I, Norheim OF, Svilaas A, Kristiansen IS, Thürmer H, Flottorp S.

BMC Med. 2012 Apr 5;10:33. doi: 10.1186/1741-7015-10-33. Review.

12.

Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.

Parsons JK, Schenk JM, Arnold KB, Messer K, Till C, Thompson IM, Kristal AR; Prostate Cancer Prevention Trial; Urologic Diseases in America Project.

Eur Urol. 2012 Aug;62(2):234-41. doi: 10.1016/j.eururo.2012.03.007. Epub 2012 Mar 14.

13.

Newer is not always better: all antihypertensive medications do not equally reduce cardiovascular risk.

Smetana GW.

J Gen Intern Med. 2012 Jun;27(6):618-20. doi: 10.1007/s11606-012-2020-x. No abstract available.

14.

Nonselective β-blocker propranolol for orbital and periorbital hemangiomas in infants: a new first-line of treatment?

El-Essawy R, Galal R, Abdelbaki S.

Clin Ophthalmol. 2011;5:1639-44. doi: 10.2147/OPTH.S24141. Epub 2011 Nov 18.

15.

Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects.

Muntner P, Mann D, Wildman RP, Shimbo D, Fuster V, Woodward M.

Am Heart J. 2011 Apr;161(4):719-25. doi: 10.1016/j.ahj.2010.12.019.

16.

Clinical trials of antihypertensives: Nature of control and design.

Chakraborty BS.

Indian J Pharmacol. 2011 Feb;43(1):13-7. doi: 10.4103/0253-7613.75659.

17.

Cost implications of improving blood pressure management among U.S. adults.

Nuckols TK, Aledort JE, Adams J, Lai J, Go MH, Keesey J, McGlynn E.

Health Serv Res. 2011 Aug;46(4):1124-57. doi: 10.1111/j.1475-6773.2010.01239.x. Epub 2011 Feb 9.

18.

Physician and patient influences on provider performance: β-blockers in postmyocardial infarction management in the MI-Plus study.

Funkhouser E, Houston TK, Levine DA, Richman J, Allison JJ, Kiefe CI.

Circ Cardiovasc Qual Outcomes. 2011 Jan 1;4(1):99-106. doi: 10.1161/CIRCOUTCOMES.110.942318. Epub 2010 Dec 7.

20.

Hypertension, the changing pattern of drug usage.

Opie LH.

Cardiovasc J Afr. 2009 Jan-Feb;20(1):52-6. Review.

Supplemental Content

Support Center